Recursion plans to utilize this data to train causal AI models to accelerate drug discovery, design biomarkers, and develop patient stratification strategies across a range of disease states.

Recursion Pharmaceuticals has a prescription for high drug costs: AI and 25 petabytes of data Growing interest in AI-powered drug discovery draws some big investors–and regulatory questions ...

--The business combination of two AI-powered drug discovery and development companies, Recursion and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion ...

Recursion Pharmaceuticals has agreed to acquire the Oxford, U.K.-based artificial intelligence (AI) drug pioneer Exscientia, in a deal that consolidates two leaders in AI-based drug development ...

Nvidia-backed Recursion Pharmaceuticals said on Tuesday its experimental drug to treat a rare brain-related condition was safe and tolerable in a mid-stage study, but showed mixed results for ...

Recursion Pharmaceuticals (NASDAQ:RXRX) led a selloff among AI-driven biotechs on Tuesday after the company, backed by chipmaker Nvidia (NASDAQ:NVDA), announced initial results from a Phase 2 ...

Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future revenue, according to Needham.